The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Orthocell (OCC) has received Food and Drug Administration (FDA) 501K approval to supply and market its medical collagen product CelGro in the U.S.
  • The approval means the CelGro — or as per its recent rebrand, Striate+ — is cleared for use on dental bone and tissue regeneration procedures in an auspicious U.S. dental market
  • OCC’s Managing Director says the approval has come sooner than expected with the FDA lodgment taking place in May 2020
  • The company has hinted it could pave the way for OCC’s entry into the peripheral nerve repair market
  • OCC shares have soared well into the green by 26.1 per cent on the back of the announcement, trading at 58 cents each

Orthocell (OCC) has received Food and Drug Administration (FDA) 501K approval to supply and market its medical collagen product CelGro in the U.S.

The approval means the CelGro — or as per its recent rebrand, Striate+ — is cleared for use on dental bone and tissue regeneration procedures in the U.S. market.

A company statement indicates the dental market in the States is valued at US$500 million per annum or roughly A$645 million.

More specifically, Striate+ has been cleared for use in dental bone defect repair, augmentation around dental implants in immediate and delayed extraction sockets and tissue regeneration procedures.

Orthocell submitted an FDA application for the product in May 2020.

Striate+ is manufactured in is manufactured at Orthocell’s facilities in West Australia using the Company’s proprietary SMRTTM manufacturing technology.

The company says the FDA approval validates the SMRT manufacturing technology and could potentially pave the way for OCC’s entry into the peripheral nerve repair market.

Orthocell Managing Director, Paul Anderson, says the approval came sooner than expected.

“I am excited by this strategic milestone and the positive step it represents on our pathway to partnering Striate+ in dental GBR indications,” he commented.

Orthocell has also recently received approval to sale and market the product in Australia.

OCC shares have soared well into the green by 26.1 per cent on the back of the announcement, trading at 58 cents each at 10:45 am AEDT.

OCC by the numbers
More From The Market Online
The Market Online Video

This stock could have something close to a cure for osteoarthritis. Don’t let it hide under your nose

Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for 
The Market Online Video

AFT Pharma sets new $300M target after reaching $200M revenue for FY25

AFT Pharmaceuticals Ltd has unveiled its financial results for FY2025, announcing that it has reached a…
A Mayne Pharma worker in a lab surrounded by vials and bottles.

Mayne Pharma nosedive deepens as Cosette mulls scrapping $672M buy-up

Mayne Pharma Group (ASX:MYX) has been taking a beating in the markets this week, with company value as much
Medicaid concept

HeraMED slammed as US partner drops pregnancy tech; Medicaid changes bite

Nanocap health software company HeraMED (ASX:HMD) has been slammed on Monday as the company revealed its…